阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

盘后交易 07-02 19:15:08 EDT

76.99

-0.95

-1.22%

盘后76.82

-0.17-0.23%

19:14 EDT

最高77.42	最低76.46	成交量321.56万
今开77.31	昨收77.94	日振幅1.23%
总市值2,387亿	流通市值2,377亿	总股本31.01亿
成交额2.47亿	换手率0.10%	流通股本30.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":76.99,"timestamp":1719950400000,"preClose":77.94,"halted":0,"volume":3215608,"hourTrading":{"tag":"盘后","latestPrice":76.815,"preClose":76.99,"latestTime":"19:14 EDT","volume":260203,"amount":20033023.76594,"timestamp":1719962081199},"delay":0,"floatShares":3087945606,"shares":3100512604,"eps":2.024846,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.95,"latestTime":"07-02 19:15:08 EDT","open":77.31,"high":77.42,"low":76.46,"amount":247276701.95316,"amplitude":0.012317,"askPrice":77.4,"askSize":1203,"bidPrice":76.8,"bidSize":13,"shortable":3,"etf":0,"ttmEps":2.024846,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1719964800000},"adr":1,"listingDate":737179200000,"adjPreClose":77.94,"adrRate":0.5,"dividendRate":0.018834,"preHourTrading":{"tag":"盘前","latestPrice":77.325,"preClose":77.94,"latestTime":"09:29 EDT","volume":24963,"amount":1934359.779225,"timestamp":1719926941879},"postHourTrading":{"tag":"盘后","latestPrice":76.815,"preClose":76.99,"latestTime":"19:14 EDT","volume":260203,"amount":20033023.76594,"timestamp":1719962081199},"volumeRatio":1.046052,"optionData":{"bulkOrders":[{"symbol":"AZN","call":false,"expireDate":1722571200000,"strike":"72.0","timestamp":1719929430151,"price":0.47999998927116394,"volume":3009,"amount":144432,"type":"-"}]},"impliedVol":0.2356,"impliedVolPercentile":0.5952},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2446516584","title":"德国支持民众接种由阿斯利康和赛诺菲针对呼吸道合胞病毒联合开发的疫苗，暂时还不支持接种辉瑞制药的疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2446516584","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446516584?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:08","pubTimestamp":1719536891,"startTime":"0","endTime":"0","summary":"德国支持民众接种由 阿斯利康 和赛诺菲针对呼吸道合胞病毒联合开发的 疫苗 ，暂时还不支持接种 辉瑞制药 的疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062809171095e01ce0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062809171095e01ce0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0868494617.USD","BK4581","LU0320765992.SGD","IE00BBT3K403.USD","IE00BLSP4452.SGD","SG9999002224.SGD","SGXZ57979304.SGD","LU1057294990.SGD","BK4534","BK4533","LU2236285917.USD","IE00B19Z3B42.SGD","BK4592","LU0889565916.HKD","PFE","LU0170899867.USD","LU1023059063.AUD","LU0058720904.USD","LU0321505868.SGD","LU0122379950.USD","BK4550","SG9999001176.USD","SG9999001176.SGD","BK4568","LU0289739699.SGD","BK4588","SG9999002232.USD","SG9999003800.SGD","SG9999011175.SGD","BK4007","IE00B19Z3581.USD","AZN","IE0002270589.USD","LU1066053197.SGD","SG9999013999.USD","LU0321505439.SGD","LU1066051498.USD","LU1829250122.USD","LU0234572021.USD","LU0456855351.SGD","BK4585","LU0109394709.USD","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2446852135","title":"阿斯利康投资（中国）有限公司申请II类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2446852135","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446852135?lang=zh_cn&edition=full","pubTime":"2024-06-27 16:56","pubTimestamp":1719478594,"startTime":"0","endTime":"0","summary":"金融界6月27日消息，据CDE官网沟通交流公示，于6月27日收到阿斯利康投资（中国）有限公司申请的“II类会议”，当前状态“处理中”。根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议，就关键阶段重大问题进行沟通交流。Ⅱ类会议一般安排在申请后60日内召开，系指为药物在研发关键阶段而召开的会议，主要包括下列情形：新药临床试验申请前会议、药物Ⅱ期临床试验结束/Ⅲ期临床试验启动前会议、新药上市许可申请前会议、风险评估和控制会议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062717041095dda7ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062717041095dda7ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","LU0109394709.USD","LU1829250122.USD","BK4007","AZN","LU0320765992.SGD","LU0889565916.HKD","BK4568","LU2236285917.USD"],"gpt_icon":0},{"id":"2446254833","title":"隔夜美股全复盘(6.27)| 美光盘后一度跌逾9%，三季报超预期，下季指引不够亮眼；联邦快递收涨近16%，年度利润指引超预期，FY25将回购25亿美元股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2446254833","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446254833?lang=zh_cn&edition=full","pubTime":"2024-06-27 08:25","pubTimestamp":1719447941,"startTime":"0","endTime":"0","summary":"美光盘后一度跌逾9%，三季报超预期，下季指引不够亮眼；联邦快递收涨近16%，年度利润指引超预期，FY25将回购25亿美元股票","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/815107","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["KKR","BK4581","AAPL","PDD","IE0004445015.USD","LU0965509010.AUD","LU1551013425.SGD","LU0127658192.USD","LU0234572021.USD","LU1914381329.SGD","META","LU0170899867.USD","LU0980610538.SGD","IE00BJJMRX11.SGD","LU0642271901.SGD","BK4507","LU0820562030.AUD","LU0106831901.USD","LU1861215975.USD","LU1935043536.SGD","NVDA","SSNLF","LU0130102774.USD","IE00B19Z3581.USD","BK4574","LU1046421795.USD","MA","LU0965509101.SGD","LU1429558221.USD","JD","LU0149725797.USD","LU0690374615.EUR","FDX","IE0034235295.USD","LU","NIO","LU0690374961.EUR","LU0097036916.USD","IE00BDCRKT87.USD","LU0256863811.USD","V","IE0009356076.USD","RIVN","BABA","MU","AZN","BK4567","F","LU0320765992.SGD","IE00BMPRXR70.SGD","MSFT","AMZN","TSLA","GOOG","LU0348723411.USD","LU0823411888.USD","IE00BKVL7J92.USD","BK4561"],"gpt_icon":0},{"id":"2446352362","title":"阿斯利康肺癌靶向药联合化疗新适应证获批，肺癌精准治疗还有哪些痛点","url":"https://stock-news.laohu8.com/highlight/detail?id=2446352362","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446352362?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:17","pubTimestamp":1719393462,"startTime":"0","endTime":"0","summary":"6月26日，阿斯利康宣布，全球首个三代EGFR-TKI肺癌靶向药物奥希替尼联合化疗一线治疗EGFR突变晚期非小细胞肺癌的适应证在中国获批。奥希替尼联合化疗组患者的中位无疾病进展生存期比奥希替尼单药组延长了8.8个月。在中国，肺癌是恶性肿瘤发病和死亡的首位原因。肺癌治疗领域的进展，对癌症防治总体目标的实现具有重要意义。奥希替尼是EGFR突变阳性晚期NSCLC患者的一线治疗方案，通过奥希替尼联合化疗一线治疗可进一步让患者的生命得以延长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626171851af8f4ba0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626171851af8f4ba0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2236285917.USD","LU0320765992.SGD","BK4007","LU0109394709.USD","AZN","LU1829250122.USD","BK4585","BK4568","LU0889565916.HKD"],"gpt_icon":0},{"id":"2446324543","title":"阿斯利康：肺癌靶向药物泰瑞沙?联合化疗一线治疗EGFR突变晚期非小细胞肺癌的适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446324543","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446324543?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:39","pubTimestamp":1719383945,"startTime":"0","endTime":"0","summary":"每经AI快讯，阿斯利康6月26日宣布，中国国家药品监督管理局于2024年6月18日正式批准泰瑞沙?（英文商品名：TAGRISSO?，通用名：甲磺酸奥希替尼片，以下简称“奥希替尼”）联合培美曲塞和铂类化疗药物用于具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406263114408224.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406263114408224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","LU2236285917.USD","BK4588","BK4585","BK4007","LU1829250122.USD","LU0889565916.HKD","BK4568","LU0109394709.USD","AZN"],"gpt_icon":0},{"id":"2446331226","title":"阿斯利康肺癌靶向药泰瑞沙新适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446331226","media":"老虎证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446331226?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:20","pubTimestamp":1719382828,"startTime":"0","endTime":"0","summary":"【阿斯利康肺癌靶向药泰瑞沙新适应症在中国获批】金十数据6月26日讯，阿斯利康(AZN.O)6月26日宣布，中国国家药品监督管理局于2024年6月18日正式批准泰瑞沙®联合培美曲塞和铂类化疗药物用于具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614225395d92397&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614225395d92397&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2236285917.USD","LU0320765992.SGD","BK4007","LU0109394709.USD","AZN","LU1829250122.USD","BK4585","BK4568","LU0889565916.HKD"],"gpt_icon":0},{"id":"2446381237","title":"阿斯利康(AZN.US)肺癌药物奥希替尼新适应症在华获批 联合化疗一线治疗EGFR突变晚期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2446381237","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446381237?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:57","pubTimestamp":1719370676,"startTime":"0","endTime":"0","summary":"据悉，该药本次获批的新适应症为联合化疗一线治疗EGFR突变晚期非小细胞肺癌。目前，奥希替尼已在美国、欧盟、中国和日本等100多个国家和地区获批作为单一疗法使用，批准的适应症包括局部晚期或转移性EGFRm非小细胞肺癌患者的一线治疗，局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌患者的二线治疗，以及早期EGFRm非小细胞肺癌的辅助治疗。此外，该药还已在美国和其他一些国家获批联合化疗用于局部晚期或转移性EGFRm非小细胞肺癌患者的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0889565916.HKD","BK4588","BK4568","AZN","LU2236285917.USD","BK4585","LU0109394709.USD","BK4007","LU1829250122.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2444103503","title":"阿斯利康(AZN.US)新药Truqap联合化疗乳腺癌后期试验未达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2444103503","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444103503?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:19","pubTimestamp":1718698756,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据最新研究显示，阿斯利康的新药Truqap并没有帮助患有一种难以治疗的乳腺癌患者延长寿命。阿斯利康潜在的抗癌新药Truqap最近在美国和欧盟获得批准，可用于治疗其他类型的乳腺癌。阿斯利康负责肿瘤研发的执行副总裁Susan Galbraith表示，这项新研究的结果令人失望，但可能有助于推进对某些途径的理解。Truqap目前分别在乳腺癌和前列腺癌的后期试验中进行测试。在伦敦早盘交易中，阿斯利康的股价几乎没有变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2236285917.USD","LU0320765992.SGD","BK4007","LU1829250122.USD","BK4588","LU0109394709.USD","LU0889565916.HKD","AZN","BK4585","BK4568"],"gpt_icon":0},{"id":"2444103619","title":"阿斯利康(AZN.US)乳癌药联合化疗疗程后期临床未达生存期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2444103619","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444103619?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:12","pubTimestamp":1718698320,"startTime":"0","endTime":"0","summary":"阿斯利康(AZN.US)  (AZN.L)周二(18日)宣布，其乳癌药Truqap联合化疗药品Paclitaxel疗程(CAPItello-290)，在后期临床测试阶段未能达至改善整体生存期的目标。阿斯利康表示，由于缺乏已知可操作生物标志目标，三阴性乳癌属最难医治的疾病之一；以化疗为基础的治疗方案仍是主流做法。阿斯利康英股早段靠稳，报12,428便士。(da/k)(美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211209122201027_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211209122201027_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1357297/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2236285917.USD","BK4007","LU0109394709.USD","LU0889565916.HKD","BK4585","LU0320765992.SGD","LU1829250122.USD","AZN","BK4568","BK4588"],"gpt_icon":0},{"id":"2444017894","title":"EHA观察｜加入阿斯利康后再次公开亮相，亘喜生物继续“上分”","url":"https://stock-news.laohu8.com/highlight/detail?id=2444017894","media":"氨基观察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444017894?lang=zh_cn&edition=full","pubTime":"2024-06-18 11:16","pubTimestamp":1718680599,"startTime":"0","endTime":"0","summary":"ASCO年会之后，2024年欧洲血液学协会年会（EHA）接踵而来，各类创新成果同样精彩纷呈。作为欧洲血液学领域规模最大的国际盛会，每年都吸引着来自世界各地的专家学者到访。根据EHA官网发布的摘要统计，今年共有24篇来自中国的研究入选口头报告、184篇研究入选壁报展示以及127篇研究线上发表，同比增长27%。可以说，EHA2024继...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/Ow3TBMacKOYevWMbI-fbZBVCRuBJ-X4qsgmqAHDHmADuoAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Ow3TBMacKOYevWMbI-fbZBVCRuBJ-X4qsgmqAHDHmADuoAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240618A033AZ00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240618A033AZ00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["GRCL","LU1829250122.USD","BK4568","LU0109394709.USD","BK4535","BK4139","LU0889565916.HKD","BK4585","LU2236285917.USD","LU0320765992.SGD","AZN","BK4007","BK4588"],"gpt_icon":0},{"id":"2444153268","title":"被阿斯利康并购后，亘喜生物要进行细胞治疗药物扩产","url":"https://stock-news.laohu8.com/highlight/detail?id=2444153268","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444153268?lang=zh_cn&edition=full","pubTime":"2024-06-17 16:15","pubTimestamp":1718612130,"startTime":"0","endTime":"0","summary":"去年年底，阿斯利康宣布以约12亿美元价格并购亘喜生物，后者成为了首家被跨国药企全资并购的中国生物科技企业。被并购后，亘喜生物在加码细胞治疗药物生产。近日，亘喜生物宣布，与苏州生物医药产业园正式签署合作备忘录。根据协议，亘喜生物将深化与苏州生物医药产业园的战略合作，进一步扩展生产空间，提升细胞治疗药物产能，进一步夯实阿斯利康细胞疗法领域实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240617161705aef53cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240617161705aef53cab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4139","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","BK4585","BK4007","LU2236285917.USD","GRCL","BK4588","LU0109394709.USD","AZN","BK4568"],"gpt_icon":0},{"id":"2443600640","title":"阿斯利康Durvalumab搭配Chemo Ok'd疗法获得FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2443600640","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443600640?lang=zh_cn&edition=full","pubTime":"2024-06-15 04:20","pubTimestamp":1718396414,"startTime":"0","endTime":"0","summary":"阿斯利康Durvalumab搭配Chemo Ok'd用于治疗子宫内膜癌的疗法获得美国食品药品管理局（FDA）批准","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061504201695b187ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061504201695b187ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0109394709.USD","AZN","LU2236285917.USD","BK4568","LU1829250122.USD","BK4007","LU0889565916.HKD","BK4585","LU0320765992.SGD"],"gpt_icon":0},{"id":"2442396832","title":"阿斯利康药业中国公司增资至10.7亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2442396832","media":"天眼查","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442396832?lang=zh_cn&edition=full","pubTime":"2024-06-11 20:41","pubTimestamp":1718109699,"startTime":"0","endTime":"0","summary":"（原标题：阿斯利康药业中国公司增资至10.7亿）天眼查App显示，近日，阿斯利康药业（中国）有限公司发生工商变更，注册资本由约8.8亿人民币增至约10.7亿人民币。该公司成立于2011年6月，法定代表人为黄彬，经营范围为开发生产片剂，自营和代理各类商品及技术的进出口业务，由AstraZeneca Continent B.V.全资持股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406112047229f30ff5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406112047229f30ff5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","BK4585","LU2236285917.USD","BK4568","BK4588","BK4007","AZN","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2441046261","title":"阿斯利康投资（中国）有限公司药品纳入突破性治疗药物程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2441046261","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441046261?lang=zh_cn&edition=full","pubTime":"2024-06-08 09:15","pubTimestamp":1717809336,"startTime":"0","endTime":"0","summary":"6月8日，据CDE官网消息，阿斯利康投资（中国）有限公司联合申请的药品“甲磺酸奥希替尼片”，经审核，同意纳入突破性治疗药物程序，公示截止日期2024年6月8日。公示详细信息显示，“BDB-001注射液”药品类型为化药，拟定适应症（或功能主治）：奥希替尼用于在接受含铂根治性放化疗后未出现疾病进展、具有表皮生长因子受体(EGFR)外显子19缺失(Ex19del)或外显子21(L858R)置换突变的局部晚期，不可切除(III期)非小细胞肺癌(NSCLC)成人患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240608091538959a1838&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240608091538959a1838&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4588","LU1829250122.USD","BK4007","LU0109394709.USD","AZN","BK4568","LU0320765992.SGD","BK4585","LU2236285917.USD"],"gpt_icon":0},{"id":"2441290119","title":"西比曼/阿斯利康(AZN.US)公布CAR-T疗法治疗肝癌临床数据 DCR超91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441290119","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441290119?lang=zh_cn&edition=full","pubTime":"2024-06-05 11:14","pubTimestamp":1717557244,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月4日，西比曼宣布在2024年美国临床肿瘤学会年会上以口头报告的形式公布了C-CAR031首次人体IIT的初步安全性和有效性结果。资料显示，C-CAR031为一款新型GPC3靶向CAR-T，基于西比曼和阿斯利康的联合开发协议在中国共同开发。截至2024年3月14日，共有24例患者接受了4个剂量水平的C-CAR031输注。西比曼生物董事长兼首席执行官刘必佐先生表示，他们对C-CAR031在晚期肝细胞癌患者中的首次临床结果感到鼓舞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1131226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CAR","LU1829250122.USD","BK4588","AZN","BK4007","BK4568","BK4230","BK4022","LU0320765992.SGD","LU2236285917.USD","BK4585","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2441251411","title":"健康巡讲：阿斯利康药物在试验中多年控制肺癌类型","url":"https://stock-news.laohu8.com/highlight/detail?id=2441251411","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441251411?lang=zh_cn&edition=full","pubTime":"2024-06-05 02:53","pubTimestamp":1717527216,"startTime":"0","endTime":"0","summary":"阿斯利康药物可使无法手术的肺癌患者多年保持病情稳定 一项晚期试验的数据显示，阿斯利康公司  的Tagrisso帮助一种无法手术的非小细胞肺癌患者，在病情开始恶化前，患者的寿命超过了三年。Tagrisso 已在 100 多个国家获批用于治疗不同阶段和类型的表皮生长因子受体突变 NSCLC。早期试验显示晚期肝癌有望治愈研究人员周二在芝加哥举行的ASCO会议上报告说，一种实验性药物在对其他疗法无效的晚期肝癌患者进行的一项小型早期试验中取得了令人鼓舞的结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","BK4007","LU0109394709.USD","LU0889565916.HKD","BK4585","LU0320765992.SGD","LU1829250122.USD","AZN","BK4568","BK4588"],"gpt_icon":0},{"id":"2440493490","title":"阿斯利康乳腺癌ADC药物有望进一步扩大使用范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2440493490","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440493490?lang=zh_cn&edition=full","pubTime":"2024-06-03 21:01","pubTimestamp":1717419660,"startTime":"0","endTime":"0","summary":"根据阿斯利康和第一三共于当地时间6月2日公布的最新数据，其针对乳腺癌的一款ADC药物德曲妥珠单抗可延缓乳腺癌进展速度。阿斯利康表示，正在与全球监管机构合作，提交最新的Enhertu乳腺癌数据。阿斯利康援引数据显示，约70%的乳腺癌患者是激素受体阳性，这些患者最初用干扰雌激素等激素的内分泌药物治疗。乳腺癌是第二大常见的癌症，也是全球癌症相关死亡的主要原因之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603210153af8ba5e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603210153af8ba5e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","LU0889565916.HKD","BK4568","AZN","ADC","BK4588","LU2236285917.USD","BK4585","LU0109394709.USD","BK4007","LU1829250122.USD","LU0320765992.SGD","BK4231"],"gpt_icon":0},{"id":"2440516964","title":"优赫得针对接受一线或多线内分泌治疗后的HR 阳，HER2 低表达和HER2-ultralow转移性乳腺癌患者的mPFS达13.2个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2440516964","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440516964?lang=zh_cn&edition=full","pubTime":"2024-06-03 16:16","pubTimestamp":1717402560,"startTime":"0","endTime":"0","summary":"预先指定的亚组分析显示，在HER2 低表达患者和HER2-ultralow患者中具有临床意义的无进展生存期改善是一致的。DESTINY-Breast06的中位无进展生存期超过一年，这表明德曲妥珠单抗可以成为HER2低表达和HER2-ultralow在转移性肿瘤患者内分泌治疗后的一种新的治疗标准。在整个试验人群中，德曲妥珠单抗的客观缓解率为57.3%，对比化疗的为31.2%；在HER2-ultralow患者中，德曲妥珠单抗的客观缓解率为61.8%，对比化疗的为26.3%。德曲妥珠单抗治疗组的13名患者出现了完全缓解，其中包括9名HER2低表达患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4429340_ZH29340_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AZN","LU0320765992.SGD","LU1829250122.USD","BK4225","LU0889565916.HKD","LU0109394709.USD","BK4568","BK4007","BK4588","HR","BK4203","BK4585","LU2236285917.USD"],"gpt_icon":0},{"id":"2440102866","title":"阿斯利康：临床研究显示靶向抗癌药泰瑞沙将无进展生存期延长3年以上","url":"https://stock-news.laohu8.com/highlight/detail?id=2440102866","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440102866?lang=zh_cn&edition=full","pubTime":"2024-06-03 07:49","pubTimestamp":1717372148,"startTime":"0","endTime":"0","summary":"当地时间6月2日，阿斯利康宣布，LAURA Ⅲ期试验的积极结果显示，Tagrisso与安慰剂相比，对肿瘤有外显子19缺失或外显子21突变的不可切除的Ⅲ期表皮生长因子受体突变非小细胞肺癌患者进行化放疗后的无进展生存期有统计学意义和高度临床意义的改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406030825309587f4bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406030825309587f4bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2236285917.USD","BK4568","BK4585","BK4007","LU0320765992.SGD","AZN","LU0889565916.HKD","LU1829250122.USD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2440889970","title":"结果未达预期，剑指肺癌乳腺癌的ADC药物上市蒙尘","url":"https://stock-news.laohu8.com/highlight/detail?id=2440889970","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440889970?lang=zh_cn&edition=full","pubTime":"2024-06-01 10:45","pubTimestamp":1717209900,"startTime":"0","endTime":"0","summary":"2024年，FDA加速批准其用于治疗不可切除获转移性的HER2阳性实体瘤，使其成为首款获批不限癌种适应证的HER2靶向ADC疗法。此次TROPION-Lung01试验公布的差强人意的OS结果，使首个治疗肺癌的TROP2 ADC之争增添悬念。此前，FDA有基于PFS获益批准药物的先例。最终FDA基于PFS获益结果加速批准阿替利珠单抗的PD-L1阳性TNBC适应证，并要求确证性III期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060110460595828df6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060110460595828df6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","LU0320765992.SGD","LU1829250122.USD","LU0889565916.HKD","BK4080","BK4231","LU0109394709.USD","BK4568","BK4007","BK4588","ADC","BK4585","LU2236285917.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.018},{"period":"1month","weight":-0.001},{"period":"3month","weight":0.1633},{"period":"6month","weight":0.1408},{"period":"1year","weight":0.089},{"period":"ytd","weight":0.1572}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0341},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1633},{"period":"1year","weight":0.2302},{"period":"ytd","weight":0.1473}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.483871,"avgChangeRate":-0.001106},{"month":2,"riseRate":0.387097,"avgChangeRate":-0.020166},{"month":3,"riseRate":0.580645,"avgChangeRate":0.030042},{"month":4,"riseRate":0.677419,"avgChangeRate":0.03301},{"month":5,"riseRate":0.516129,"avgChangeRate":0.008567},{"month":6,"riseRate":0.46875,"avgChangeRate":0.020173},{"month":7,"riseRate":0.5625,"avgChangeRate":-0.004512},{"month":8,"riseRate":0.451613,"avgChangeRate":-0.00136},{"month":9,"riseRate":0.580645,"avgChangeRate":0.00617},{"month":10,"riseRate":0.548387,"avgChangeRate":0.016698},{"month":11,"riseRate":0.516129,"avgChangeRate":0.001567},{"month":12,"riseRate":0.580645,"avgChangeRate":0.009222}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}